Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (
NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class ActionShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (
NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (
NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 - UNCYLevi & Korsinsky, LLP notifies institutional investors in Unicycive Therapeutics, Inc. (
NASDAQ: UNCY) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff RoleIf you have suffered a loss on your Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (
NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm to Learn About Their Legal RightsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (
NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026 inclusive (the “Class Period”).
Law Offices of Frank R. Cruz Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (
NASDAQ: UNCY) common stock between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). Unicycive Therapeutics, Inc. investors have until November 2, 2026 to file a lead plaintiff motion.
UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“” or the “Company”) (
NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Deadline Approaching: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (
NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”).
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their RightsRosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (
NASDAQ: UNCY) between December 29, 2025 and June 29, 2026. Unicycive describes itself as a “a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases.”
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (
NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (
NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”).
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCYThe DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (
NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (
NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLPThe law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Unicycive Therapeutics (“Unicycive” or the “Company”) (
NASDAQ: UNCY) securities during the period of December 29, 2025 through June 29, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (
NASDAQ: UNCY) common stock between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). Unicycive Therapeutics, Inc. investors have until November 2, 2026 to file a lead plaintiff motion.
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action
Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (
NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.
